Fund Overview
The Australian Smaller Companies Fund has been rewarding investors with attractive returns and income since its inception in 1998. The fund rigorously applies our proven investment philosophy to identify and invest in high-quality, undervalued companies outside the ASX100. It has been managed by Simon Conn for more than 20 years and is now co-managed by Lucas Goode.
- Suitable for: investors wanting attractive capital growth and income
- Invests in: 50-70 Australian companies outside the ASX 100
- Investment timeframe: 4+ years
- Investment objective: exceed the returns of the S&P/ASX Small Ordinaries index (ex Property Trusts) on a rolling four-year basis.
Fund Facts
Portfolio Managers | Simon Conn & Lucas Goode |
Benchmark | S&P/ASX Small Ordinaries Index (ex Property Trusts) |
Inception | 30 June 1998 |
ARSN | 093 182 471 |
APIR | IML0001AU |
Distribution frequency | Generally semi-annually |
Peformance fee | nil |
Management fee | 0.993% p.a. of the net assets of the fund (includes net effect of GST) |
Performance
1mth | 3mth | 6mth | 1yr | 2yrs^ | 3yrs^ | 5yrs^ | 10yrs^ | Since inception^ |
|
---|---|---|---|---|---|---|---|---|---|
Income | 0.0% | 0.0% | 2.3% | 4.3% | 4.7% | 8.2% | 7.7% | 10.0% | 10.6% |
Growth | 5.1% | 6.2% | 4.1% | 23.7% | 13.5% | -4.3% | -0.4% | -1.2% | 2.2% |
Total Return | 5.1% | 6.2% | 6.4% | 28.0% | 18.2% | 3.9% | 7.3% | 8.8% | 12.8% |
Benchmark* | 5.3% | 5.6% | 1.3% | 17.6% | 12.8% | -0.8% | 4.5% | 6.7% | 5.9% |
^ Performance per annum
* The benchmark for this fund is the S&P/ASX Small Ordinaries Index (Ex. LPT).
Fund returns are calculated using the exit price, net of management fees, assuming all distributions are reinvested with no allowance for tax. Past performance is not a reliable indicator future performance.
Sector and stocks
Company Name | ASX code | Sector | % weight |
---|---|---|---|
Australian Clinical Labs Limited | ACL | Health Care | 3.0% |
Clearview Wealth Limited | CVW | Financials | 3.0% |
Kelsian Group Limited | KLS | Industrials | 2.8% |
Ridley Corporation Limited | RIC | Consumer Staples | 2.7% |
Trajan Group Holdings Limited | TRJ | Health Care | 2.7% |
Integral Diagnostics Limited | IDX | Health Care | 2.7% |
Readytech Holdings Limited | RDY | Information Technology | 2.7% |
Global Data Centre Group | GDC | Information Technology | 2.6% |
Hansen Technologies Limited | HSN | Information Technology | 2.6% |
Austal Limited | ASB | Industrials | 2.4% |
Fund holdings as at 30 Sep 2024
Unit Prices
Date | Entry | Exit |
---|---|---|
04 Oct 2024 | $1.7880 | $1.7790 |
03 Oct 2024 | $1.7878 | $1.7788 |
02 Oct 2024 | $1.7845 | $1.7756 |
01 Oct 2024 | $1.7816 | $1.7728 |
30 Sep 2024 | $1.7744 | $1.7656 |
Distribution information
Period ending | Amount (cents per unit) |
---|---|
June 2024 | 3.5877 cpu |
December 2023 | 2.0000 cpu |
June 2023 | 3.8738 cpu |
December 2022 | 2.5000 cpu |
June 2022 | 19.1897 cpu |
December 2021 | 7.0000 cpu |
June 2021 | 12.7159 cpu |
December 2020 | 1.5000 cpu |
For more information please refer to our Performance page – distributions and reports.
Past performance is not a reliable indicator of future performance as a result past distributions are not indicative of future distributions.
Past performance is not a reliable indicator of future performance as a result past distributions are not indicative of future distributions.
Franking level (%) | ||||
---|---|---|---|---|
FY23 | FY22 | FY21 | FY20 | FY19 |
79.9% | 13.5% | 21.9% | 71.2% | 44.7% |
This is not tax advice. it is important that you seek professional taxation advice that takes into account your particular circumstances before you invest or deal with your investment.
Ratings and awards
Morningstar - Silver
Zenith - Recommended
How to invest
Direct investors can click Invest Now for a step-by-step guide to investing with IML. The Australian Smaller Companies Fund is also available on the following platforms:
Aegis (NZ) | AMP North | ANZ/IOOF Oasis | Asgard | BT Panorama | CFS Firstwrap | FNZ (NZ) | Growwrap | Hub 24 | Infocus | Insignia Expand | Insignia Pursuit | Insignia Rhythm | Macquarie Wrap | Mason Stevens | Netwealth | Portfolio Care | Powerwap | Praemium | Dash
© 2024 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report or data has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Morningstar’s publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser.
The Zenith Investment Partners (“Zenith”) Australian Financial Services License No. 226872 rating (assigned 27 February 2024) referred to in this document is limited to “General Advice” (as defined by the Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Zenith usually charges the product issuer, fund manager or a related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessment’s and at http://www.zenithpartners.com.au/RegulatoryGuidelines
The rating issued 09/2023 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved.
Zenith Investment Partners Pty Ltd ABN 27 103 132 672 AFSL 226872 Fund Awards issued (18 October 2024) are solely statements of opinion and not a recommendation in relation to making any investment decisions. Fund Awards are current for 12 months and subject to change at any time. Fund Awards for previous years are for historical purposes only. Full details on Zenith Fund Awards at https://www.zenithpartners.com.au/zenith-fund-awards-2024/
INVESTMENT INSIGHTS & PERFORMANCE UPDATES
Subscribe to receive IML’s regular performance updates, invitations to webinars as well as regular insights from IML’s investment team, featured in the Natixis Investment Managers Expert Collective newsletter.
IML marketing in Australia is distributed by Natixis Investment Managers, a related entity. Your subscriber details are being collected by Natixis Investment Managers Australia, on behalf of IML. Please refer to our Privacy Policy. Natixis Investment Managers Australia Pty Limited (ABN 60 088 786 289) (AFSL No. 246830) is authorised to provide financial services to wholesale clients and to provide only general financial product advice to retail clients.